The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy
Authors
Keywords
-
Journal
JOURNAL OF CELLULAR BIOCHEMISTRY
Volume 118, Issue 12, Pages 4163-4169
Publisher
Wiley
Online
2017-05-05
DOI
10.1002/jcb.26118
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Practice guidelines for management of cervical cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement
- (2017) Myong Cheol Lim et al. Journal of Gynecologic Oncology
- Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer
- (2017) Daniela Massihnia et al. Journal of Hematology & Oncology
- Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening
- (2015) Robert A. Smith et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway
- (2015) H. Lou et al. CLINICAL CANCER RESEARCH
- PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathway
- (2015) Xiang-Rong Shu et al. Diagnostic Pathology
- Dehydrocostus Lactone Inhibits Proliferation, Antiapoptosis, and Invasion of Cervical Cancer Cells Through PI3K/Akt Signaling Pathway
- (2015) Enping Jiang et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Genetic variations in the PI3K/AKT pathway predict platinum-based neoadjuvant chemotherapeutic sensitivity in squamous cervical cancer
- (2015) Lu Guo et al. LIFE SCIENCES
- PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis
- (2015) Min-Sik Lee et al. Nature Communications
- PI3K/AKT pathway-mediated regulation of p27Kip1 is associated with cell cycle arrest and apoptosis in cervical cancer
- (2015) Shyam Babu Prasad et al. CELLULAR ONCOLOGY
- Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience
- (2015) Ming-Mo Hou et al. Oncotarget
- Improved Clearance during Treatment of HPV-Positive Head and Neck Cancer through mTOR Inhibition
- (2015) Joseph D. Coppock et al. NEOPLASIA
- CD38 is highly expressed and affects the PI3K/Akt signaling pathway in cervical cancer
- (2014) SHAN LIAO et al. ONCOLOGY REPORTS
- Oncogenic mutations in cervical cancer
- (2013) Alexi A. Wright et al. CANCER
- Phosphatidylinositol 3-kinase Signaling as a Therapeutic Target for Cervical Cancer
- (2013) Jianghong Wu et al. CURRENT CANCER DRUG TARGETS
- Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)
- (2013) A.V. Tinker et al. GYNECOLOGIC ONCOLOGY
- A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins
- (2013) Stephen B. Keysar et al. Molecular Oncology
- Landscape of genomic alterations in cervical carcinomas
- (2013) Akinyemi I. Ojesina et al. NATURE
- Multiplex Identification of Human Papillomavirus 16 DNA Integration Sites in Cervical Carcinomas
- (2013) Bo Xu et al. PLoS One
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer
- (2012) Ivan Diaz-Padilla et al. CANCER TREATMENT REVIEWS
- Pathway-Specific Analysis of Gene Expression Data Identifies the PI3K/Akt Pathway as a Novel Therapeutic Target in Cervical Cancer
- (2012) Julie K. Schwarz et al. CLINICAL CANCER RESEARCH
- mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas
- (2012) A. A. Molinolo et al. CLINICAL CANCER RESEARCH
- PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy
- (2012) John B. McIntyre et al. GYNECOLOGIC ONCOLOGY
- Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer
- (2012) Peng Guan et al. INTERNATIONAL JOURNAL OF CANCER
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations
- (2012) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies
- (2010) Sarah M. Temkin et al. GYNECOLOGIC ONCOLOGY
- High expression of mTOR is associated with radiation resistance in cervical cancer
- (2010) Min-Kyu Kim et al. Journal of Gynecologic Oncology
- Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
- (2010) Silvia de Sanjose et al. LANCET ONCOLOGY
- Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer
- (2008) Xiao-Yan Zhang et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy
- (2007) Leri S. Faried et al. MOLECULAR CARCINOGENESIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now